Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by forhandlarenon Mar 27, 2024 12:18pm
89 Views
Post# 35955740

RE:Shareprice 35% below pp price

RE:Shareprice 35% below pp priceThe current private placement was a great mistake by management. They had already secured cash for another 6 to 7 months by tax returns and loan. Why not wait for some excitment over the new plans kick in? Possibly also an anti-aging deal for a region they won't launch in.

I think that potential participants tried to sell shares in order to finance their participation with warrents attached to the new shares - but - existing shareholders want material progress like Abbvie launch before they buy more shares, no matter the price. Thereby the price goes south and if they lower the price to 5 cents the same story repeats.

The easy way out to save the private placement is the replace Howard with more or less anyone. The price would immediately surge. I wouldn't mind a junior CEO. Why not a woman with interest in the beauty market?!

<< Previous
Bullboard Posts
Next >>